ONO 7268MX1

Drug Profile

ONO 7268MX1

Alternative Names: ONO-7268 MX1; Peptide-cocktail vaccine for hepatocellular carcinoma - OncoTherapy Science/Ono Pharmaceutical

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoTherapy Science
  • Developer Ono Pharmaceutical
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 28 Jul 2017 Discontinued - Phase-I for Hepatocellular carcinoma in Japan (SC) (Ono Pharmaceutical pipeline, July 2017)
  • 05 May 2016 Phase I development is ongoing in Japan
  • 02 Aug 2012 Phase-I clinical trials in Hepatocellular carcinoma in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top